News
Pitfalls with Oral Drug Administration in IPF
In the first 3 parts of our blog series on targeted delivery in idiopathic pulmonary fibrosis (IPF), we focused on the potential of inhaled delivery and other
Thoughts from the Extracellular Matrix Pharmacology Symposium
Last week the TherapeutAix team participated in the excellent Extracellular Matrix Pharmacology Symposium, hosted by our network partner Nordic Bioscience. This was a 2-day virtual event, with more than 500 scientists
It’s Rare Disease Day
Worldwide, 473 million people suffer from a rare disease1. But every single one of these diseases is not frequent at all – with some just occurring in a handful
Targeting Drug Effects in IPF
In the first two parts of our blog series on drug delivery in idiopathic pulmonary fibrosis (IPF), we focused on inhalation. In this third instalment,
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12 months. Here’s a recap. A
Challenges in inhaled drug therapy
In the first blog of this series1, we highlighted that, despite the potential advantages, there appear to be only a few opportunities pursuing the inhaled
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib, need to be considered when